Imatinib (Gleevec®), an inhibitor designed to target the BCR-ABL fusion complex in chronic myelogenous leukemia (CML), was the first successful drug in this category and exemplifies the therapeutic potential of these drugs. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.